Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TY-0305 (cibenzoline) in symptomatic hypertrophic obstructive cardiomyopathy
jRCT2080224827Phase 2Completed
- Sponsor
- TOA EIYO
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cibenzoline in Hypertrophic Obstructive Cardiomyopathy (HOCM), sponsored by TOA EIYO. Started Aug 2019; status: completed.
02
Drugs
cibenzoline
03
Conditions
Hypertrophic Obstructive Cardiomyopathy (HOCM)
Beyond the preview
Go deeper on jRCT2080224827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224827.